AbCellera Biologics (ABCL) EPS (Weighted Average and Diluted): 2019-2024
Historic EPS (Weighted Average and Diluted) for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$0.55.
- AbCellera Biologics' EPS (Weighted Average and Diluted) fell 70.00% to -$0.17 in Q4 2023 from the same period last year, while for Dec 2023 it was -$0.52, marking a year-over-year decrease of 204.00%. This contributed to the annual value of -$0.55 for FY2024, which is 7.84% down from last year.
- Per AbCellera Biologics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.55 for FY2024, which was down 7.84% from -$0.51 recorded in FY2023.
- In the past 5 years, AbCellera Biologics' EPS (Weighted Average and Diluted) registered a high of $0.50 during FY2022, and its lowest value of -$0.55 during FY2024.
- Over the past 3 years, AbCellera Biologics' median EPS (Weighted Average and Diluted) value was -$0.51 (recorded in 2023), while the average stood at -$0.19.
- In the last 5 years, AbCellera Biologics' EPS (Weighted Average and Diluted) spiked by 4,600.00% in 2020 and then plummeted by 202.00% in 2023.
- Over the past 5 years, AbCellera Biologics' EPS (Weighted Average and Diluted) (Yearly) stood at $0.45 in 2020, then climbed by 6.67% to $0.48 in 2021, then grew by 4.17% to $0.50 in 2022, then plummeted by 202.00% to -$0.51 in 2023, then declined by 7.84% to -$0.55 in 2024.